Clinical features of flare in Japanese patients with new-onset SLE and risk factors for SLE flare in daily clinical practice: a single-center cohort study

• Published in: Immunological medicine pp. 1 - 8
• Main Authors: Sato, Shuzo, Yoshida, Shuhei, Sumichika, Yuya, Saito, Kenji, Matsumoto, Haruki, Temmoku, Jumpei, Fujita, Yuya, Matsuoka, Naoki, Asano, Tomoyuki, Migita, Kiyoshi
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis Group 03.06.2024
• Subjects: Anti-SSA antibodies; clinical features; flare; risk factor; systemic lupus erythematosus; Anti-SSA antibodies; flare; systemic lupus erythematosus; risk factor; clinical features
• ISSN: 2578-5826
• DOI: 10.1080/25785826.2024.2360664

This study aimed to elucidate the clinical features, outcomes and risk factors of flares in patients with systemic lupus erythematosus (SLE). Data were collected from patients with newly diagnosed SLE at the Fukushima Medical University Hospital between 2011 and 2022. Patients who experienced a flare during the study period constituted the flare group, and their clinical features were compared with those of the no-flare group. The cumulative flare-free survival regarding several clinical items was compared between the two groups using Kaplan-Meier's curves. Among 387 patients with SLE, 83 patients with newly diagnosed SLE were included. Their mean age was 37.9 years, and 29 patients experienced flares during the study period. The general characteristics were similar between the two groups, with the exception of the observation period and anti-SS-A antibody positivity. Regarding therapy, a significantly increased frequency of hydroxychloroquine intake and combination with immunosuppressive agents were observed in the no-flare group. The Kaplan-Meier analysis revealed a significantly higher cumulative flare-free survival in the anti-SS-A negative group and combination immunosuppressive therapy group. In conclusion, anti-SS-A positivity may be a risk factor for SLE flare. In turn, combination immunosuppressive therapy may be beneficial for SLE treatment in daily clinical practice.